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ABSTRACT
To investigate the frequency and the prognostic impact of fibroblast growth factor 
receptor 1 (FGFR1) gene amplification in 526 curatively resected esophageal squamous 
cell carcinoma (ESCC). Using fluorescent in situ hybridization, high amplification was 
defined by an FGFR1/centromer 8 ratio is ≥ 2.0, or average number of FGFR1 signals/
tumor cell nucleus ≥ 6.0, or percentage of tumor cells containing ≥ 15 FGFR1 signals 
or large cluster in ≥ 10%. Low amplification was defined by ≥ 5 FGFR1 signals in ≥ 
50%. FGFR2 and FGFR3 mutations were assessed by direct sequencing in 388 cases 
and no mutation was detected. High and low amplification were detected in 8.6% and 
1.1%, respectively. High FGFR1 amplification had significantly shorter disease-free 
survival (34.0 vs 158.5 months P=0.019) and overall survival (52.2 vs not reached 
P=0.022) than low/no amplification group. After adjusting for sex, smoking, stage, 
histology, and adjuvant treatment, high FGFR1 amplification had a greater risk 
of recurrence (adjusted hazard ratio [AHR], 1.6; P=0.029) and death (AHR, 1.53; 
P=0.050). High amplification was significantly higher in current smokers than former 
and never‑smokers (Ptrend<0.001) and increased proportional to smoking dosage. 
High FGFR1 amplification is a frequent oncogenic alteration and an independent poor 
prognostic factor in resected ESCC. 
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INTRODUCTION
Esophageal cancer (EC) is the sixth most common 
cause of cancer death worldwide [1]. Despite the 
improvement of surgical technique and medical treatment, 
prognosis remains poor, with 5-year survival rate of 
less than 40%.[2] EC consists of two major histologic 
subtypes; esophageal squamous cell carcinoma (ESCC) 
and adenocarcinoma (EAC). Both histologic subtypes 
have different risk factors and epidemiology. ESCC 
continues to be the major subtype of EC in Asia, and the 
main risk factors include smoking and alcohol abuse.[3] In 
contrast, EAC predominately affects the Caucasian, and is 
closely associated with gastroesophageal reflux disease, 
Barrett’s esophagus, and obesity. [4-7] Compared with 
ESCC, EAC shows younger age onset, male predominance 
and frequent occurrence in distal third of the esophagus.
[8] Given widely different epidemiological and clinical 
features, EAC and ESCC may represent distinct disease 
entities which may benefit from different therapeutic 
approaches.
Amplification and overexpression of human 
epidermal growth factor receptor 2 (HER2; also known 
as ERBB2) was more frequent in EAC than ESCC and 
there was a strong concordance of HER2 status in primary 
and metastatic cancer.[9] Therefore, various clinical trials 
evaluating the efficacy of HER2 targeting agents were 
reported for the patients with advanced esophageal and 
esophagogastric junction (EGJ) adenocarcinoma.8-10 In the 
phase II trials for HER2 amplified EGJ adenocarcinoma, 
lapatinib, a dual tyrosine kinase inhibitor of ERBB1 
and HER2 demonstrated modest response.[10, 11] The 
therapeutic implication of HER2 protein overexpression 
or gene amplification has been demonstrated in the 
Trastuzumab for Gastric Cancer (ToGA) trial [12]. In this 
trial, addition of trastuzumab (anti-HER2 antibody) to 
standard chemotherapy significantly improved response 
rate, progression-free survival and overall survival 
compared with chemotherapy alone in HER2-positive 
advanced gastric and EGJ adenocarcinoma. Based on 
the results of the ToGA trial, HER2 testing is routinely 
recommended for all patients with metastatic gastric 
or EGJ adenocarcinoma, and trastuzumab should be 
considered for HER2-positive cases. 
Despite a rapid and enthusiastic development of 
targeted therapies in gastric or EGJ adenocarcinoma, no 
therapeutically tractable target has been identified for 
ESCC. Recently, comparative genomic analysis showed 
different DNA copy number alterations between EAC and 
ESCC.[13, 14] Among those, high copy number gains of 
cancer-associated genes, such as SOX2, PIK3CA, CCND1, 
and FGFR1, were more frequently observed in ESCC than 
in EAC, suggesting that genomic gain of these oncogenes 
may be therapeutic targets for ESCC. 
Fibroblast growth factor receptor 1 (FGFR1) is a 
member of family of receptor tyrosine kinases (FGFR1-
4), and its activation by amplification, mutation, or 
translocation leads to tumor cell proliferation and survival 
in many cancers.[15, 16] Potentially actionable FGFR 
rearrangements were identified in diverse solid tumors 
including lung cancer, oral cancer, and breast cancer. [17-
19] FGFR1 amplification has been frequently reported 
in lung squamous cell carcinoma (SqCC), small cell 
lung cancer, and SqCC of head and neck (SCCHN), for 
which smoking is a clear and dominant risk factor.[15, 16, 
20-28] Overall, the frequency of FGFR1 amplification 
was reported to be 5.6%-24.8% in lung SqCC and 15%-
17.4% in SCCHN, suggesting that this genetic alteration 
mainly target squamous cell histology.[16, 20-25, 27, 28] 
Furthermore, FGFR1 amplification has been associated 
with poor prognosis or unfavorable clinicopathologic 
parameters in lung SqCC and SCCHN. Because ESCC has 
risk factors in common with lung SqCC and SCCHN, we 
hypothesized that FGFR1 amplifications is associated with 
pathogenesis and poor prognosis in ESCC. 
In this study, we sought to determine the frequency, 
prognostic impact and association with smoking dosage 
of FGFR1 amplification in surgically resected ESCC. 
Furthermore, we also evaluated the frequency of FGFR2 
and FGFR3 mutations in ESCC. 
RESULTS
Patient Characteristics
A total of 526 Korean patients who underwent 
curative esophagectomy were analyzed. The clinical 
characteristics of the enrolled patients are presented 
in Table 1. There were 489 male and 37 female with a 
median age of 66 years (range 35-98). Median tumor size 
was 3 cm and approximately half of tumors had pT3 or 
pN0. Pathologic stages were I in 22.4%, II in 42.8%, and 
III in 34.8%. Two thirds (60.3%) were located in the lower 
esophagus, and more than half of patients had moderately 
differentiated SqCCs. The majority of patients were 
current (39.0%) or former smokers (38.6%), and median 
smoking dosage was 30.0 pack-years (range 0-150). 
Adjuvant treatment was given in 140 patients (26.6%), 
and 87 of those (62.1%) were treated by concurrent 
chemoradiotherapy. The proportions of adjuvant therapy 
according to stage were 5.9% in stage I, 21.8% in stage II, 
and 45.9% in stage III.
FGFR1 amplification status and clinicopathologic 
features
Among 526 patients, 45 (8.6%) were high FGFR1 
amplification, 6 (1.1%) were low FGFR1 amplification, 
and 475 (90.3%) displayed no amplification (Table 1; 
Figure 1). The median FGFR1 gene copy number per 
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Table 1: Patient characteristics according to FGFR1 amplification 
Characteristics All patients High amplification* Low amplification* No amplification 
No. % No. % No. % No. % P†
No of patients 526 100 45 8.6 6 1.1 475 90.3
Age, years 0.697
Median (range) 66 (35-98) 67 (52-77) 68 (65-77) 66 (35-98)
Sex 0.608
  Male 489 93.0 43 95.6 6 100 440 92.6
  Female 37 7.0 2 4.4 0 0 35 7.4
Tumor size, cm 0.310
  Median, range 3.0 (0.2-10.5) 3.0 (2.0-9.0) 2.5 (2.0-4.5) 3.0 (0.2-10.5)
pT stage‡ 0.618
  T1 167 31.7 12 26.7 2 33.3 153 32.2
  T2 106 20.2 12 26.7 1 16.7 93 19.6
  T3 238 45.2 18 40.0 3 50.0 217 45.7
  T4 15 2.9 3 6.7 0 0 12 2.5
pN stage‡ 0.619
  N0 259 49.2 22 48.9 3 50.0 234 49.3
  N1 234 44.5 20 44.4 2 33.3 212 44.6
  N2 22 4.2 3 6.7 1 16.7 18 3.8
  N3 11 2.1 0 0 0 0 11 2.3
pTMN stage‡ 0.822
 I 118 22.4 8 17.8 1 16.7 109 22.9
 II 225 42.8 19 42.2 2 33.3 204 42.9
 III 183 34.8 18 40.0 3 50.0 162 34.1
Location 0.158
 Upper 66 12.5 5 11.1 0 0 61 12.8
 Middle 143 27.2 19 42.2 2 33.3 122 25.7
 Lower 317 60.3 21 46.7 4 66.7 292 61.5
Tumor grade 0.424
 Well 128 24.3 12 26.7 2 33.3 114 24.0
 Moderate 314 59.7 29 64.4 4 66.7 281 59.2
 Poorly 84 16.0 4 8.9 0 0 80 16.8
Smoking status¶ <0.001
 Never-smoker 118 22.4 1 2.2 0 0 117 24.6
 Former smoker 203 38.6 5 11.1 2 33.3 196 41.3
 Current smoker 205 39.0 39 86.7 4 66.7 162 34.1
Smoking dosage, pack-
years
 Median 30 39 35 30 0.002
 Range 0-150 0-99 13-60 0-150
Adjuvant therapy 0.870
   Yes 140 26.6 13 28.9 2 33.3 125 26.3
   No 386 73.4 32 71.1 4 66.7 350 73.7
FGFR1 FISH§
  Number
(median, range) 2.2 (0-15.5) 6.4 (4.1-15.5) 5.1 (5.0-5.6) 2.2 (0-5.7) <0.001
Ratio 
(mean, range) 1.5 (0-7.8) 2.9 (1.1-7.8) 1.5(1.0-1.9) 1.3 (0-1.6) 0.003
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nucleus and the mean FGFR1/CEN8 ratio in all patients 
were 2.2 (range, 0 to 15.5 copies per nucleus) and 1.5 
(range, 0 to 7.8). The median FGFR1 gene copy number 
was 6.4 (range, 4.1 to 15.5) in high amplification, 5.1 
(range, 5.0 to 5.6) in low amplification, and 2.2 (range 
0 to 5.7) in no amplification group. The mean FGFR1/
CEN8 ratio was 2.9 (range 1.1 to 7.8), 1.5 (range, 1.0 
to 1.9), and 1.3 (range, 0 to 1.6) in high, low and no 
amplification group, respectively. Of 45 high FGFR1 
amplified tumors, 12 cases (26.7%) only satisfied the 
criterion of an FGFR1:CEN8 ratio of ≥ 2.0, 7 cases 
(15.6%) only satisfied the criterion of an average number 
of FGFR1 signal per nucleus ≥6.0, and 4 cases (8.9%) 
only satisfied the criterion of percentage of tumor cells 
containing ≥ 15 FGFR1 signals or large clusters in ≥ 10% 
cells, respectively. 22 cases (48.9%) satisfied all three 
criteria for FGFR1 amplification simultaneously. 
There was no significant difference among three 
FGFR groups regarding age, sex, tumor size, pathologic 
stage, location, histologic grade, and adjuvant therapy 
(Table 1). However, the incidence of high FGFR1 
amplification was significantly higher in smokers than in 
never-smokers (P<0.001). Only 1 (2.2%) of 45 patients 
with high-level amplification was never smoker. The 
median smoking dosage was significantly higher for high 
amplification group than that for low or no amplification 
group (39 vs 35 vs 30 pack-years, P=0.002). Based on the 
pattern of high amplification (group fulfilling 3 criteria vs. 
1 or 2 criteria), there was no significant difference in terms 
of age, sex, location, and pathologic stage.
Survival Outcomes According to FGFR1 
Amplification
With a median follow-up time of 55.4 months, the 
5 year DFS and OS rates for all patients were 52.8% and 
59.8%, respectively. The 5-year DFS rate according to 
pTNM stages were 78.4% in stage I, 55.9% in stage II, and 
33.2% in stage III patients. The 5-year OS rate according 
to pTNM stages were 86.8% for stage I, 65.3% for stage 
II, and 37.1% for stage III. 
The median DFS for each of the three FGFR groups 
was 34.0 months in the high FGFR1 amplification, not 
reached (NR) in low amplification group, and 158.5 
months in the no amplification group (Figure 2A). By 
using pair-wise comparison, patients with high FGFR1 
amplification showed a significantly shorter DFS than 
those with no amplification (34.0 vs 158.5 months in 
no amplification, P=0.020). The median DFS of high 
amplification and low amplification were not significantly 
different (34.0 vs NR in low amplification, P=0.272), 
probably due to small sample size in the low amplification 
group. The median DFS was similar between low 
amplification and no amplification group in pair-wise 
Abbreviations: 
*High FGFR1 amplification was defined as if one of the following criteria is fulfilled: (1) FGFR1/CEN8 ratio is ≥ 2.0, (2) 
average number of FGFR1 signal per nucleus ≥ 6.0, and (3) percentage of tumor cells containing ≥ 15 FGFR1 signals or large 
clusters in ≥ 10% cells. Low FGFR1 amplification was defined when the percentage of tumor cells containing ≥ 5 FGFR1 
signals is ≥ 50 %.
†χ2 test, Fisher’s exact test, or Mann-Whitney U test.
‡Pathologic stage at the time of surgical resection was determined according to the American Joint Committee on Cancer 
(seventh edition) guidelines.
¶Never-smokers; a lifetime smoking dose of fewer than 100 cigarettes; former smokers, those who have stopped smoking for 
more than 1 year; current smokers, those who currently smoke or have quit for less than 1 year.
§ FGFR1 numbers are average numbers of FGFR1 signals per nucleus, and ratios are FGFR1/CEN8 ratios. 
Figure 1: Fibroblast growth factor receptor 1 (FGFR1) amplification assessed by fluorescent in situ hybridization. (A) 
High FGFR1 amplification; (B) Low FGFR1 amplification; (C) No amplification.
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comparison (P=0.639). The median OS for each of the 
three FGFR groups was 52.2 months in the high FGFR1 
amplification, 72.0 months in the low amplification, 
and not reached in the no amplification (Figure 2B). By 
using pair-wise comparison, patients with high FGFR1 
amplification showed a significantly shorter OS than those 
with no amplification (52.2 vs NR in no amplification, 
P=0.021). The OS times of high amplification and low 
amplification were not significantly different (52.2 vs 
72.0 in low amplification, P=0.637), probably due to 
small sample size in the low amplification group. The 
median OS was similar between low amplification and no 
amplification group in pair-wise comparison (P=0.517).
Because the DFS of patients with low and no 
amplification were similar but different from that of 
patients with high amplification, we categorized total 
patients into high amplification group and low/no 
amplification group and assessed the survival outcomes 
Table 2: Survival outcome in multivariate analysis 
DFS OS
Variable Category HR 95% CI P HR 95% CI P
Sex Male vs female (ref) 0.91 0. 53-1.55 0.724 0.90 0.53-1.54 0.703
Smoking status
Current smoker vs 
never/former-smoker 
(ref)
1.08 0.82-1.43 0.595 1.02 0.77-1.35 0.898
Pathologic stage* III vs II/I (ref) 2.56 1.97-3.34 <0.001 2.53 1.94-3.29 <0.001
Histology Poor vs well/moderate(ref) 1.61 1.16-2.22 0.004 1.61 1.17-2.23 0.004
Adjuvant treatment Yes vs no (ref) 1.11 0.82-1.50 0.497 1.05 0.78-1.43 0.731
FGFR1 amplification High vs Low /no (ref) 1.61 1.05-2.46 0.029 1.53 0.99-2.34 0.050
Abbreviations: DFS, disease-free survival; OS, overall survival; ref, reference; amp, amplification;
* Clinical stage at the time of initial diagnosis was determined according to the American Joint Committee on Cancer 
(seventh edition) guidelines.
Figure 2: Survival analysis on the basis of FGFR1 amplification (high, low, and no amplification). (A) Median DFS was 
34.0 months in the high FGFR1 amplification group, not reached in low amplification group, and 158.5 months in the no amplification 
group. (B) The median OS was 52.2 months in the high FGFR1 amplification group, and 72.0 months in the low amplification group, and 
not reached in the no amplification group.
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of these two groups. The median DFS of the high FGFR1 
amplification group was significantly shorter compared 
with that of the low/no FGFR1 amplification group (34.0 
vs 158.5 months P=0.019, Figure 3A). In addition, high 
FGFR1 amplification group demonstrated significantly 
shorter OS than low/no FGFR1 amplification group (52.2 
vs NR, P=0.022, Figure 3B). In Cox proportional hazard 
model adjusted for sex, smoking history, pathologic 
stage, adjuvant treatment, and histologic grade, high 
FGFR1 amplification was significantly associated with 
a shorter DFS (AHR 1.61; 95% CI, 1.05-2.46; P=0.029, 
table 2). There was a strong trend toward worse OS for 
high FGFR1 amplification compare to low/no FGFR1 
amplification group in multivariate analysis (HR 1.53; 
95% CI, 0.99-2.34, P=0.050). There was no significant 
difference in DFS and OS for sex, smoking status, and 
adjuvant treatment in multivariate analysis. There was 
no significant difference in DFS and OS between group 
fulfilling 3 criteria and group fulfilling 1 or 2 criteria.
FGFR2 and FGFR3 mutations
FGFR2 and FGFR3 mutations were assessed by 
direct sequencing in 388 cases with FFPE tissues available 
and no FGFR2 or FGFR3 mutation was detected. 
Association between FGFR1 amplification and 
smoking
As shown in Figure 4A, the incidence of high-level 
FGFR1 amplification was significantly higher in current 
smokers than former or never-smokers (Ptrend <0.001). The 
incidences of high-level FGFR1 amplification in current, 
former and never-smokers were 19.0%, 2.5%, and 0.8%, 
respectively. With increment of total cigarette smoking 
dosage, the incidence of high-level FGFR1 amplification 
was significantly increased (Figure 4B, Ptrend = 0.001). 
High-level FGFR1 amplification were 0.8% for never-
smokers, 5.8% in patients with 1-10 pack-years, 7.4% with 
11-20 pack-years, 9.6% with 21-50 pack-years, and 19.3% 
with more than 50 pack-years. 
DISCUSSION
In this study, we investigated the frequency and the 
prognostic impact of FGFR1 amplification in resected 
ESCC. To our knowledge, this is the first report on the 
prognostic impact of FGFR1 amplification in the largest-
ever cohort of resected ESCC patients from East Asian. 
Our study demonstrated high FGFR1 amplification is a 
common genetic alteration (8.6%) and an independent 
negative prognostic factor in resected ESCC. Interestingly, 
it was associated with cigarette smoking in a dose-
dependent manner.
Figure 3: Prognostic impact of high FGFR1 amplification and low/no amplification on DFS and OS. (A) The median 
DFS of the high FGFR1 amplification group was significantly shorter compared with low/no FGFR1 amplification group (P=0.019) (B) 
The median OS of high FGFR1 amplification group demonstrated significantly shorter than low/no FGFR1 amplification group (P=0.022).
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The frequency of FGFR1 amplification has been 
reported to range from 6% to 9.4%. In the DNA array 
hybridization study,[29] 2 out of 32 ESCC cases (6%) 
demonstrated amplified 8p11 locus which containing 
FGFR1 gene. A comparative genomic study revealed 
many focal DNA amplifications or losses such as SOX2, 
PIK3CA, CCND1, FGFR1, MYC, GATA4, and GATA6 
in ESCC and EAC.[13] Of note, FGFR1 was amplified 
in 21% of ESCC samples compare with 8% in EAC. 
Recently, FGFR1 amplification was reported to be 9.4% 
in the cohort with Western Europe.[30] The frequency of 
high FGFR1 amplification (8.6%), as determined by FISH 
analysis in our study, was comparable to those reported 
in previous studies.[13, 29, 30] Given the relatively high 
frequency of FGFR1 amplification, it may represent an 
attractive therapeutic target for ESCC.
Given the histological similarity and common risk 
factors, it is not surprising that FGFR1 amplification 
has been reported in upper aerodigestive tract cancers 
such as lung SqCC, SCCHN, and small cell lung cancer.
[16, 20-28] However, the prognostic significance of 
FGFR1 amplification in these cancers has shown 
controversial results. In resected lung SqCC, Kim 
et al[16] reported FGFR1 amplification as negative 
prognostic factor, whereas Heist et al [24] observed 
no significant difference in OS. In SCCHN, FGFR1 
amplification was significantly associated with poor 
prognostic factors such as higher T stage, lymphovascular 
invasion, and higher numbers of visceral metastases.[22]
Tumor heterogeneity, unstandardized FISH criteria for 
FGFR1 amplification, varying adjuvant treatment, and 
small sample size may contribute to the controversial 
results. In our study, by applying more sophisticated 
criteria for FGFR1 amplification, we were able to divide 
FGFR1 amplification into high and low amplification. 
Low FGFR1 amplification occurred only in 1.1% and 
survival outcome of low FGFR1 amplification group was 
similar to no amplification group. Compared with low/
no amplification group, high FGFR1 amplification was 
significantly associated with shorter DFS regardless of 
sex, histology, and adjuvant therapy, implying that FGFR1 
amplification as an independent negative prognostic factor 
in curatively resected ESCC.
The identification of FGFR alteration in human 
cancers led to rapid development of selective FGFR 
inhibitor such as BGJ398 and AZD4547. In phase I study 
with BGJ398,[31] 1 patient with FGFR1 amplified lung 
SqCC with FGFR1/CEN8 ratio of 2.6 by FISH analysis 
had partial response. In another phase I study with FGFR 
inhibitor AZD4547,[32] 1 partial response was also seen 
in lung SqCC patient with FGFR1 amplification (FGFR1/
CEN8 ratio > 2.8). Various FGFR inhibitors are currently 
in clinical development for the patients with FGFR 
aberrations. Therefore, our study strongly suggests the 
therapeutic potential of FGFR inhibitor for ESCC, and 
future clinical trials for advanced high FGFR1 amplified 
ESCC are strongly warranted. 
Unfortunately, FISH criteria for FGFR1 
amplification has not yet been standardized. Indeed, 
definition of FGFR1 amplification by FISH technique 
has been highly variable in the previous studies in lung 
cancer and breast cancer.[16, 24, 25, 28, 33, 34] Unlike 
breast cancer, lung SqCC exhibits small-clusters and 
co-amplifications of FGFR1 and CEN8.[25] Therefore, 
FGFR1 FISH assay needs to differentiate between true 
amplification and polysomy. In a large cohort study, 
Schildhause et al [25] proposed a more sophisticated 
FGFR1 FISH criteria using average gene copy number 
per nucleus, FGFR1/CEN8 ratio, and percentage of gene 
clusters at the same time. By the addition of FGFR1/CEN8 
Figure 4: Association of smoking status and high FGFR1 amplification. (A) Proportions of high FGFR1 amplification according 
to never-, former, and current smokers (B) Incidence of high FGFR1 amplification according to smoking dosage.
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ratio, 8 out of 47 cases (17.0%) were newly classified 
as high amplification in this study.(25) Similarly, in our 
study, 12 out of 45 high amplification group (26.7%) 
might have been misclassified as low/no amplification 
group if the criterion for FGFR1/CEN8 ratio was not 
included. Considering clinical benefit appeared in patients 
with high FGFR1/CEN8 ratio in clinical trials with FGFR 
inhibitors,[31, 32] this scoring system might serve as a 
standardized screening tool to select patients who gain 
greater benefit from treatment with FGFR inhibitors. Our 
criteria need further validation in the future clinical trials 
with FGFR inhibitors in ESCC patients.
Accumulating evidence has shown that FGFR1 
amplification correlated with smoking status in squamous 
cell biology. FGFR1 amplification occurs significantly 
more often in the smokers of the lung SqCC, SCCHN, 
and small cell lung cancer.[16, 22, 23, 26] The proportion 
of FGFR1 amplification among current smokers were 
reported 15.8% to 28.9% in lung SqCC and 17.7% in 
SCCHN in a dose dependent manner.[16, 22, 23] In small 
cell lung cancer cohort, all FGFR1 amplified cases were 
current or former smokers.[26] In our study, FGFR1 
amplification was significantly more likely to be smokers, 
and 44 out of 45 high FGFR1 amplification cases were 
current or former smokers. Similar to the findings in lung 
SqCC and SCCHN, acquisition of FGFR1 amplification 
in our study was also significantly increased proportional 
to smoking dosage. Therefore, FGFR1 amplification may 
be an oncogenic driver mutation in tobacco-associated 
cancers of the aerodigestive tract. An interesting question 
of the role of FGFR1 amplification on the smoking-
associated carcinogenesis still remained to be solved. 
Somatic mutations of FGFR2 and FGFR3 were 
reported in 12% and 30% of endometrial and urothelial 
cell carcinomas, respectively.[35, 36] Inhibitor–sensitive 
5 mutation loci for FGFR2 and 6 mutation loci for 
FGFR3 were noticed in 3% of lung SqCC samples.[37]
Here, we show no FGFR2 and FGFR3 mutations in our 
388 ESCC patients. This may be explained by the limited 
sensitivity of the Sanger sequencing, tumor heterogeneity 
or molecular difference of ESCC from lung SqCC. 
The main limitation of our study include its 
retrospective nature and patient selection. Therefore, our 
findings should be validated in an independent cohort and 
response data to FGFR-targeted therapies in the future 
clinical trials.
In conclusion, we demonstrated high FGFR1 
amplification is an independent poor prognostic factor in 
resected ESCC. Patients with FGFR1 amplification were 
significantly more likely to be smokers and the frequency 
of FGFR1 amplification was also increased proportional 
to smoking dosage, suggesting FGFR1 amplification as 
an oncogenic aberration induced by smoking carcinogen. 
Our finding indicates FGFR1 amplification is a promising 
therapeutic target in ESCC.
PATIENTS AND METHODS
Patients and tissue samples
This study was conducted in a cohort of patients 
with ESCC who underwent radical esophagectomy at 
Severance Hospital and Samsung Medical Center, Seoul, 
Korea, between 2002 and 2010. The criteria used for 
patient selection included (1) surgically resected SqCC of 
the thoracic esophagus (R0 resection), (2) availability of 
primary tumor tissue, (3) no distant metastasis, and (4) no 
preoperative treatment. The tumor samples of 664 patients 
were available for examination of FGFR1 amplification. 
We excluded 115 cases (17.3%) who received neoadjuvant 
treatment. Twenty-three patients (3.5%) were excluded 
because of incomplete survival follow-up and/or smoking 
data. All diagnosis were reviewed by two experienced 
pathologist (Y.L.C. and H.K.K) and confirmed by 
hematoxylin and eosin staining. Three representative cores 
measuring in 2-mm-diameter for each paraffin-embedded 
primary tumor were assembled into tissue microarray 
blocks.
Patients’ information was collected by reviewing 
the medical records for evaluation of clinicopathologic 
characteristics and survival outcome. Staging was 
determined using the 7th edition American Joint 
Committee on Cancer guideline of tumor, node, and 
metastasis (TNM) classification. Smoking status such as 
never-smoker, former smoker, and current smoker were 
defined as previous studies.[38] The study was approved 
by the institutional review board of Severance Hospital 
and Samsung Medical Center. 
FGFR1 Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) to detect 
FGFR1 amplification was performed at the chromosomal 
level of the tissue microarray. We performed fluorescence 
signal detection with two probes on chromosome 8. The 
target probe is located on the FGFR1 locus spanning 
8p12 - 8p11.23 with spectrum orange (red) and CEN 8 
with Spectrum Green (Abbott Molecular, Abbott Park, 
IL) following routine method. The evaluation was done 
independently by two experienced pathologists (Y.L.C. 
and H.K.) blinded to clinical information, and at least 
100 nuclei per case were evaluated. FGFR1 amplification 
was defined based on the previous studies.[25, 26] 
High FGFR1 amplification was defined as if one of the 
following criteria is fulfilled: (1) FGFR1/CEN8 ratio is 
≥ 2.0, (2) average number of FGFR1 signal per nucleus 
≥ 6.0, and (3) percentage of tumor cells containing ≥ 
15 FGFR1 signals or large clusters in ≥ 10% cells. Low 
FGFR1 amplification was defined when the percentage of 
tumor cells containing ≥ 5 FGFR1 signals is ≥ 50%. 
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Mutation analysis
Genomic DNA was extracted from 388 formalin-
fixed paraffin-embedded (FFPE) tissue specimens using 
an QIAamp DNA Micro kit (Qiagen, CA, USA) according 
to the manufacturer’s instruction. The extracted DNA 
was used in a PCR amplification reaction. Based on 
the previous study in lung SqCC,[37] we evaluated the 
W290C, S320C, and K660E/K660N mutations in FGFR2, 
and R248C and S249C mutations in FGFR3. PCR 
amplification primers were designed to amplify following 
regions; W290C; 5’-TCCACAGTGGTCGGAGGAG-3’; 
5’- AAAGTCCTCACCTTGAGAACCTTG-3’, 
S320C; 5’-CCTGGTTGGCCGTTATATTG-3’; 
5’- TGTTTTGGCAGGACAGTGAG-3’, K660E/
K660N; 5’- ATTCATCGAGATTTAGCAGCCAG 
-3’; 5’- ACATTCTGAGCCTCACCCC -3’, R248C 
and S249C; 5’-TGGCGGTGGTGGTGAG-3’; 5’- 
ATTCACCTCCACGTGCTTGA-3’.
PCR was carried out with the following conditions 
: initial denaturation at 95°C for 10 min, followed by 45 
cycles for 30 s, 54°C for 60 s, 72°C for 45 s and final 
polymerization step of 72°C for 5 min in a GeneAmp 
PCR system 2720 (Life technologies, CA, USA). 
The amplified DNA product was visualized by gel 
electrophoresis and PCR products were sequenced using 
the Big dye terminator sequencing kit (Life technologies, 
CA, USA) according to the manufactures’ instruction. 
Sequence reactions were the subjected to electrophoresis 
on an Applied Biosystems 3130XL DNA Analyzer (Life 
technologies, CA, USA).
Statistical Analysis
We evaluated association between FGFR1 
amplification status and clinical significance using the χ2 
test or Fisher’s exact test and trend was analyzed using 
linear regression. We also assessed whether FGFR1 
amplification influenced survival outcome using Kaplan-
Meier curves with a log-rank test. Disease free survival 
(DFS) was defined from the time of surgery to initial 
relapse or death. Overall survival (OS) was measured 
from the time of surgery to death or last follow-up date, 
and 95% CIs were evaluated by survival analysis using the 
Kaplan-Meier method. Statistical significance was set at 
P < 0.05 for all analyses. Multivariate analysis was done 
using Cox regression analysis for following variables: sex, 
smoking status, stage, histology, adjuvant treatment, and 
FGFR1 status. All statistical analysis was performed using 
SPSS version 18.0 (SPSS, Chicago, IL). 
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